Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01522911|
Recruitment Status : Unknown
Verified January 2012 by Nicolas Majunke, University of Leipzig.
Recruitment status was: Active, not recruiting
First Posted : February 1, 2012
Last Update Posted : February 1, 2012
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation Stroke Prevention Left Atrial Appendage||Device: WATCHMAN LAA system (Percutaneous left atrial appendage closure)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Interventional Study to Investigate the Effects of Percutaneous Closure of the Left Atrial Appendage on Atrial and Brain Natriuretic Peptide Secretion|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||January 2012|
|Estimated Study Completion Date :||January 2012|
atrial and brain natriuretic peptide
Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
Device: WATCHMAN LAA system (Percutaneous left atrial appendage closure)
The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
- Change from Baseline Plasma ANP and BNP levels after transcatheter closure of the left atrial appendage. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 48 hours ]Venous blood samples are taken before the procedure, immediately after implantation of the LAA closure device and on the first morning after the procedure. The blood is drawn into plastic tubes containing aprotinin and ethylenediaminetetraacetic acid disodium and is promptly centrifuged. The plasma obtained is stored at -20°C until assayed. The plasma BNP and ANP concentrations are then determined with a commercially available enzyme immunoassay kit (ELISA Kit for Brain Natriuretic Peptide, Uscn Life Science Inc., Missouri City, USA and ANP ELISA Kit, Hölzel Diagnostika, Köln, Germany).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522911
|Principal Investigator:||Nicolas Majunke, M.D.||HearCenter Leipzig|
|Principal Investigator:||Sven Moebius-Winkler, M.D.||HearCenter Leipzig|
|Principal Investigator:||Gerhard Schuler, Professor||HearCenter Leipzig|